At KPMG, we provide strategic advice to clients working at the forefront of the next generation of therapies – cell and gene technologies. We support cell and gene therapy clients in a number of ways, such as:
• We bring a strategic view to the challenges and opportunities associated with the development, manufacturing, supply, regulation, pricing and commercialisation of these therapies.
• We advise clients in assessing major investment and innovation choices.
• We undertake buy-side or sell-side due diligence.
• We assist clients in determining the tax impact of business decisions
David WalshLife Sciences Strategy
KPMG Strategy 00353014101000